# Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

> **NCT06829641** · — · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 200 (estimated)

## Conditions studied

- NSCLC Stage IIIB, NSCLC Stage IIIC

## Interventions

- **PROCEDURE:** Tislelizumab Combined with Chemotherapy,

## Key facts

- **NCT ID:** NCT06829641
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-09
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829641, "Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06829641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*